# A Phase I, Open-Label, Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide in Healthy Chinese Participants

> **NCT03276052** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 20 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Aclidinium Bromide 400 μg

## Key facts

- **NCT ID:** NCT03276052
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-14
- **Primary completion:** 2021-11-26
- **Final completion:** 2021-11-26
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2023-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03276052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03276052, "A Phase I, Open-Label, Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide in Healthy Chinese Participants". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03276052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*